Vioxx: Too Risky for Merck?
This case follows Merck's pharmaceutical product, Vioxx, from initial development to launch and subsequent withdrawal, and considers the decisions made at each stage by the Merck executives involved. The case concludes by examining the financial impact of the Vioxx withdrawal on the company and on the Merck stock value.
Mitchell A. Petersen, Rashmi Singhal
Petersen, A. Mitchell, and Rashmi Singhal. Vioxx: Too Risky for Merck?. Case 5-207-253 (KEL289).